World Anti-Doping Agency (WADA) announced on Monday that it will not appeal Iga Swiatek's one-month suspension for failing a drug test. WADA deemed Swiatek's explanation for the failed test as 'plausible.'
Swiatek, a five-time Grand Slam champion and former No. 1-ranked women's tennis player, recently advanced to the Australian Open quarterfinals with a dominant victory.
Unlike Swiatek's case, WADA has appealed the exoneration of men's No. 1 player Jannik Sinner, with a hearing scheduled at the Court of Arbitration for Sport (CAS) in April. Sinner was not suspended despite two positive tests for an anabolic steroid in March, as the International Tennis Integrity Agency (ITIA) found him not negligent.
Swiatek's case was resolved by the ITIA in late November, with the athlete accepting a one-month suspension after testing positive for the banned substance trimetazidine, a heart medication. The ITIA accepted Swiatek's explanation that the positive result was unintentional and caused by contamination of a non-prescription medication she was taking for jet lag and sleeping issues.
WADA consulted external legal counsel, who confirmed that Swiatek's contamination explanation was well evidenced and compliant with anti-doping regulations. The agency found no reasonable basis to appeal the decision to CAS.
Swiatek described her suspension period as 'chaotic' and 'the worst time in my life,' emphasizing that the low level of the substance in her urine indicated contamination. She expressed relief at getting closure on the matter and being able to focus on her tennis career.
Swiatek's case highlights the complexities of anti-doping regulations and the importance of thorough investigations to ensure fair outcomes for athletes.
For more tennis news, visit AP tennis.
